Constellation Pharmaceuticals Investor Presentation — January 2019

Document content

Stellar Science, Breakthrough Medicine

Jigar Raythatha, CEO, Constellation Pharmaceuticals

37thAnnual J.P. Morgan Healthcare Conference

January 9, 2019Developing Next -Generation

Epigenetic Treatments for

This presentation contains “forward -looking statements” within the meaning of the Private Securities Litigation Reform Act of 19 95 that involve

substantial risks and uncertainties, including statements regarding the development status of the Company’s product candidate s, the

anticipated benefits of the changes to its clinical trial protocols and its anticipated achievement of milestones, including determination of proof

of concept. All statements, other than statements of historical facts, contained in this press release, including statements regarding the

Company’s strategy, future operations, future financial position, prospects, plans and objectives of management, are forward -looking

statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential ,” “predict,” “project,”

“should,” “target,” “will,” “would” and similar expressions are intended to identify forward -looking statements, although not al l forward -looking

statements contain these identifying words. Any forward -looking statements are based on management’s current expectations of fut ure

events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and advers elyfrom those set

forth in, or implied by, such forward -looking statements. These risks and uncertainties include, but are not limited to, risks a ssociated with

Constellation’s ability to: obtain and maintain necessary approvals from the FDA and other regulatory authorities; continue t o advance its

product candidates in clinical trials; replicate in later clinical trials positive results found in preclinical studies and e arly-stage clinical trials of

CPI-1205, CPI -0610 and its other product candidates; advance the development of its product candidates under the timelines it an ticipates,

or at all, in current and future clinical trials; obtain, maintain or protect intellectual property rights related to its pro duct candidates; manage

expenses; and raise the substantial additional capital needed to achieve its business objectives. For a discussion of other r isks and

uncertainties, any of which could cause the Company’s actual results to differ from those contained in the forward -looking state ments, see the

“Risk Factors” section, as well as discussions of potential risks, uncertainties, and other important factors, in the Company ’s most recent